(Alliance News) - Kolinpharma Spa reported on Tuesday that the double-digit growth in the number of medical prescriptions from medical representatives continued in the fourth quarter, recording a record quarter at 202,724, up 11 percent from 183,336 in the fourth quarter of 2021.

In terms of values, the growth is even higher, standing at 15 percent compared to the same period last year.

These results were achieved with the number of medical reps, as of December 31, 2022, at 76 compared to 85 as of December 31, 2021. In addition, in January 2023, an additional eight new sales representatives were brought into the company.

Rita Paola Petrelli, president of Kolinpharma, commented, "The fourth quarter closes positively with the number of medical prescriptions exceeding 200,000 for the first time, confirming the double-digit growth trend recorded during the previous quarters, both in terms of volumes and values. This result also testifies to the consolidation of the Kolinpharma brand in the nutraceutical market in Italy. Activities for the development of the Asian market also continue in parallel following the agreement with the multinational AstaReal AB, particularly with the go live of marketing campaigns on some social media and e-commerce platforms in China."

Kolinpharma's stock is up 0.6 percent at EUR2.55 per share.

By Giuseppe Fabio Ciccomascolo, Alliance News senior reporter

Comments and questions to redazione@alliancenews.com

Copyright 2023 Alliance News IS Italian Service Ltd. All rights reserved.